MASH Drug Development Executives Sell Large Amounts of Company Stock Near Peak

On January 9, it was disclosed that former CEO Paul A. Friedman and founder Rebecca Taub of MASH drug developer Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) exercised stock options and subsequently sold tens of thousands of shares—combining newly acquired and previously held shares—on the open market at prices ranging from approximately $512 to $546 per share. Under pre-established Rule 10b5-1 trading plans, the two executives secured several hundred billion Korean won in cash but stated they still hold hundreds of thousands of shares, both directly and indirectly.

The company also announced an inducement equity compensation plan for new Chief Accounting Officer Rita Thakkar, granting her approximately 2,400 restricted stock units (RSUs) and around 1,800 stock options, pursuant to Nasdaq Listing Rule 5635(c). Additionally, Madrigal is expanding its liver disease pipeline with a focus on combination therapies through a licensing agreement with Pfizer to in-license a DGAT2 inhibitor and early-stage MASH assets. (biospace.com)

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a U.S. biopharmaceutical company dedicated to developing treatments for metabolic dysfunction–associated steatohepatitis (MASH). Following the FDA approval of its first oral drug, Rezdiffra, the company reported preliminary net sales of approximately $180 million (about KRW 230 billion) in 2024. Madrigal is reinforcing its leadership in MASH treatment by conducting follow-on MAESTRO-series clinical trials, pursuing European market entry, and securing additional patents. (globenewswire.com)